Skip to content
← Myeloproliferative Neoplasms

HEALTH PROFESSIONAL · SOURCE READING

Disease Overview for Chronic Eosinophilic Leukemia (CEL)

Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 27, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Chronic Eosinophilic Leukemia

CEL is a chronic myeloproliferative neoplasm of unknown etiology in which a clonal proliferation of eosinophilic precursors results in persistently increased numbers of eosinophils in the blood, bone marrow, and peripheral tissues. In CEL, the eosinophil count is greater than or equal to 1.5 × 109/L.[1] To make a diagnosis of CEL, there should be evidence for clonality of the eosinophils or an increase in blasts in the blood or bone marrow. However, in many cases, it is impossible to prove clonality of the eosinophils, in which case, if there is no increase in blast cells, the diagnosis of idiopathic hypereosinophilic syndrome (HES) is preferred. Because of the difficulty in distinguishing CEL from HES, the true incidence of these diseases is unknown, although they are rare. In about 10% of patients, eosinophilia is detected incidentally. In others, the constitutional symptoms found include:[1,2]

Source links and citations

Fever.

Fatigue.

Cough.

Angioedema.

Muscle pains.

Pruritus.

Diarrhea.

No single or specific cytogenetic or molecular genetic abnormality has been identified in CEL.

For more information about the symptoms listed above, see Hot Flashes and Night Sweats, Fatigue, Cardiopulmonary Syndromes, Pruritus, and Gastrointestinal Complications.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice